|
Video: What is a Stock Split?
|
|
Milestone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Co.'s product candidate etripamil is a short-acting calcium channel blocker that Co. designed as a rapid-onset nasal spray to be self-administered by patients. Co. is developing etripamil for the treatment of specific arrhythmias with a lead indication to treat paroxysmal supraventricular tachycardia, with subsequent indications to treat atrial fibrillation and rapid ventricular rate and other cardiovascular indications. According to our Milestone Pharmaceuticals stock split history records, Milestone Pharmaceuticals has had 0 splits. | |
|
Milestone Pharmaceuticals (MIST) has 0 splits in our Milestone Pharmaceuticals stock split history database.
Looking at the Milestone Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Milestone Pharmaceuticals shares, starting with a $10,000 purchase of MIST, presented on a split-history-adjusted basis factoring in the complete Milestone Pharmaceuticals stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
05/10/2019 |
|
End date: |
04/25/2024 |
|
Start price/share: |
$18.00 |
|
End price/share: |
$1.58 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-91.22% |
|
Average Annual Total Return: |
-38.74% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$877.94 |
|
Years: |
4.96 |
|
|
|
|
|